ASGCT Podcast Network

Terry Flotte, MD, discusses the early days and possible future of gene therapy, the use of AAV to deliver GT to targeted sites in the body, and his inspiration behind becoming a physician, scientist, and medical school dean. He spoke one-on-one with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the sixth episode of Giants of Gene Therapy!

Dr. Flotte is the Provost, Dean, and Celia and Isaac Haidak Professor at UMass Chan Medical School, with faculty appointments in the Department of Pediatrics and the Horae Gene Therapy Center. He is also a practicing pediatric pulmonologist and a prolific researcher who has authored more than 280 papers and been the principal investigator of multiple clinical gene therapy trials. Dr. Flotte is the editor-in-chief of his field’s oldest journal family, Human Gene Therapy.

In 1995, Dr. Flotte was the principal investigator for the first human use of AAV vectors, in a trial in cystic fibrosis patients. He’s currently investigating the use of gene therapy for genetic diseases that affect children, including alpha-1 antitrypsin (AAT) deficiency and lysosomal storage diseases.

Dr. Flotte has been an ASGCT member since the Society’s founding. He’s served on the board and committees, and spoken at the ASGCT Annual Meeting and other events.  

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Jennifer Doudna, PhD, shares her personal journey to co-inventing CRISPR-Cas9 for gene editing and the promise of her discovery, during a one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the fifth episode of Giants of Gene Therapy!

Dr. Doudna has been at UC Berkeley since 2002. She is a professor in the departments of Molecular and Cell Biology and Chemistry, the Li Ka Shing Chancellor’s Professor of Biomedical Science. She’s also the president and co-founder of the Innovative Genomics Institute. In 2020, Dr. Doudna earned the Nobel Prize in Chemistry for co-inventing CRISPR-Cas9 genome editing technology with Emmanuelle Charpentier, PhD.

Outside of her continued work on CRISPR technologies in the lab, Dr. Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies.

Dr. Doudna has spoken at the ASGCT Annual Meeting and will be a keynote speaker at this year's Annual Meeting in May, talking about “CRISPR Chemistry and Applications in the Clinic.”

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Drew Weissman, MD, PhD is a pioneer of mRNA technology, which has been used in more than 1 billion administered doses of COVID-19 vaccines. Weissman is the Roberts Family Professor in Vaccine Research, Director of Vaccine Research in the Infectious Disease Division, and the Director of the Institute for RNA Innovation at the University of Pennsylvania and the Perelman School of Medicine.

He co-developed the mRNA technology that made the COVID-19 vaccines possible. His inventions were used in the Pfizer and Moderna vaccines, and have the potential to treat a range of medical conditions. He is also promoting global vaccine access by working with governments and universities around the world.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Carl June, MD, shares his scientific journey, from medical research officer in the U.S. Navy to leader behind the first FDA-approved gene therapy, during his one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the third episode of Giants of Gene Therapy!

Dr. June is a professor in immunotherapy in the Department of Pathology and Laboratory Medicine at University of Pennsylvania's Perelman School of Medicine, the director of the Center for Cellular Immunotherapy, and the director of the Parker Institute for Cancer Immunotherapy at Penn. He was instrumental in bringing CAR T cells to the clinic and receiving the first FDA approval for CAR T cell therapy in 2017. 

Dr. June is a prolific researcher who has published more than 500 manuscripts. He's received numerous awards and honors and has been the founder or co-founder of many companies involved in T cell therapies. His discoveries launched a new era of cancer treatment options. Dr. June has been an ASGCT member and Annual Meeting keynote speaker.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Kathy High, MD, shares her personal and scientific journey, from hemophilia to retinal disease, during her one-on-one conversation with American Society of Gene & Cell Therapy President Hans-Peter Kiem, MD, PhD, in the second episode of ASGCT's Giants of Gene Therapy.

Dr. High is the president of therapeutics at AskBio. Before that, she was the co-founder, president, and head of research and development at Spark Therapeutics, where she oversaw the development, approval, and launch of Luxturna, the first AAV gene therapy approved for use in the United States.

Dr. High has published extensively in the space of gene therapy and received many highly prestigious awards for her work. She is also a past president of the American Society of Gene & Cell Therapy.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

David Baltimore, PhD discusses the Nobel Prize, searching for answers on an HIV vaccine, and how gene therapy could change the course of history during his one-on-one conversation with American Society of Gene & Cell Therapy President Hans-Peter Kiem, PhD in the debut episode of ASGCT's Giants of Gene Therapy.

Baltimore needs very little introduction. He is president emeritus and distinguished professor of biology at Caltech and was awarded the Nobel Prize in Physiology or Medicine in 1975 at the age of 37 for “discoveries concerning the interaction between tumor viruses and the genetic material of the cell.”

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Hello, and welcome to the American Society of Gene & Cell Therapy Podcast Network! I’m Hans-Peter Kiem, current president of ASGCT, and I’m hosting our first program, Giants of Gene Therapy. I’ll be interviewing luminaries from the world of cell and gene therapy, from scientific pioneers to Nobel laureates, about a wide range of subjects near to their hearts and expertise.

Our first episode, with guest Dr. David Baltimore, will release near the end of October, and I hope that you’ll join us each month as we welcome a new guest to Giants of Gene Therapy.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.